Q1 FYE3/2026 Fact Sheet

1. Consolidated Profit and Loss Statement

   Amounts less than the indicated unit are rounded down.

   		FYE3/2018	FYE3/2019	FYE3/2020	FYE3/2021	FYE3/2022	FYE3/2023	FYE3/2024	FYE3/2025					FYE3/2026			FYE3/2026
   		FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q4 A	FY A	Q1			H1 E*1	H2 E	FY
   														A	YoY	%			E	YoY	%
   Net Sales (Net Sales YoY) Cost of Goods Sold	M % M	42,298 ＋13.8 15,722	45,525 ＋7.6 17,703	51,761 ＋13.7 22,570	51,286 (0.9) 22,622	51,469 ＋0.4 22,634	51,750 ＋0.5 21,855	51,384 (0.7) 20,397	14,010 ＋8.2 5,427	13,974 ＋14.8 5,594	14,825 ＋12.6 5,878	13,799 ＋5.5 5,518	56,610 ＋10.2 22,419	14,616 ＋4.3 5,846	＋605	＋4.3	29,300 ＋4.7 11,900	30,000 ＋4.8 12,000	59,300 ＋4.8 23,900	＋2,689	＋4.8
   															＋418	＋7.7				＋1,480	＋6.6
   Gross Profit	M	26,576	27,822	29,191	28,664	28,835	29,895	30,986	8,583	8,380	8,946	8,280	34,191	8,769	＋186	＋2.2	17,400	18,000	35,400	＋1,208	＋3.5
   Gross Profit Margin %		62.8	61.1	56.4	55.9	56.0	57.8	60.3	61.3	60.0	60.3	60.0	60.4	60.0			59.4	60.0	59.7
   SG&A Expenses	M	15,904	17,295	18,756	18,296	18,861	19,057	20,094	5,388	5,314	5,300	5,860	21,864	5,497	＋108	＋2.0	11,100	11,400	22,500	＋635	＋2.9
   Operating Profit	M	10,671	10,526	10,434	10,367	9,973	10,837	10,892	3,194	3,065	3,646	2,419	12,326	3,272	＋77	＋2.4	6,300	6,600	12,900	＋573	＋4.7
   (Operating Profit YoY) % Operating Profit Margin %		＋13.8 25.2	(1.4) 23.1	(0.9) 20.2	(0.6) 20.2	(3.8) 19.4	＋8.7 20.9	＋0.5 21.2	＋0.6 22.8	＋33.5 21.9	＋22.5 24.6	(0.9) 17.5	＋13.2 21.8	＋2.4 22.4			＋0.6 21.5	＋8.8 22.0	＋4.7 21.8
   Non-Operating Income Non-Operating Expenses	M M	259 200	571 289	891 900	1,031 879	316 285	293 224	390 701	131 110	(42) 71	173 43	73 102	336 327	28 77	(102) (33)	(78.3) (30.0)	100 100	200 100	300 200	(36) (127)	(10.8) (39.0)
   Ordinary Profit	M	10,730	10,808	10,425	10,519	10,005	10,905	10,581	3,215	2,952	3,776	2,390	12,335	3,223	＋8	＋0.3	6,300	6,700	13,000	＋664	＋5.4
   Ordinary Profit Margin %		25.4	23.7	20.1	20.5	19.4	21.1	20.6	23.0	21.1	25.5	17.3	21.8	22.1			21.5	22.3	21.9
   Extraordinary Profit Extraordinary Loss	M M	1 116	5 12	3 4	3 5,982	44 8	100 1,217	13 19	20 11	7 4	1 20	23 326	52 362	ー 26	(20) ＋14	(100.0) ＋125.3	ー 50	ー 50	ー 100	(52) (262)	(100.0) (72.4)
   Net Profit Before Tax	M	10,615	10,801	10,425	4,540	10,041	9,789	10,575	3,224	2,955	3,757	2,087	12,024	3,197	(27)	(0.8)	6,250	6,650	12,900	＋875	＋7.3
   Tax Expenses	M	3,137	3,077	2,676	2,540	2,556	2,897	3,060	884	860	1,121	(159)	2,707	894	＋10	＋1.2	1,750	1,800	3,550	＋842	＋31.1
   Net Profit	M	7,478	7,723	7,748	2,000	7,484	6,891	7,515	2,340	2,094	2,635	2,246	9,317	2,302	(37)	(1.6)	4,500	4,850	9,350	＋32	＋0.3
   Net Profit % %		17.7	17.0	15.0	3.9	14.5	13.3	14.6	16.7	15.0	17.8	16.3	16.5	15.8			15.4	16.2	15.8

   EPS

   98.51

   96.05

   96.55

   24.91

   93.13

   88.22

   98.73

   31.95

   29.88

   37.60

   32.05

   131.43

   32.85

   64.17

   69.13

   133.30

   Proprietary Sales Mix %	55.4	54.9	50.7	49.9	52.4	54.9	58.8	58.2	57.0	57.6	56.7	57.4	55.6			56.9	59.4	58.1
   Internatinal Sales Mix %	ー	ー	ー	ー	ー	ー	1.4	2.0	2.0	1.9	1.7	1.9	2.4			2.2	2.0	2.1

   R&D Expenses (A)	M	1,121	1,431	1,743	1,667	2,159	2,316	2,366	538	588	527	1,196	2,851	662	＋123	＋22.9	1,607	1,591	3,198	＋347	＋12.2
   Clinical Trials & Regulatory Expenses (B)	M	126	100	80	69	306	19	70	29	33	34	25	123	33	＋3	＋12.9	91	82	174	＋51	＋41.8
   R&D Investments (A)+(B)	M	1,247	1,532	1,823	1,737	2,465	2,335	2,436	568	621	562	1,222	2,974	695	＋127	＋22.4	1,698	1,674	3,373	＋398	＋13.4
   Capital Expenditure	M	3,630	1,248	2,536	1,382	1,633	976	3,568	316	364	721	223	1,626	230	(86)	(27.3)	1,040	1,450	2,490	＋864	＋53.1
   Depreciation Expenses	M	953	1,176	1,264	1,525	1,611	1,566	1,471	424	437	455	462	1,779	404	(19)	(4.7)	815	847	1,663	(116)	(6.5)

   *1 Disclosed on May 7, 2025

2. Consolidated Balance Sheet

   Amounts less than the indicated unit are rounded down.

   		FYE3/2018	FYE3/2019	FYE3/2020	FYE3/2021	FYE3/2022	FYE3/2023	FYE3/2024	FYE3/2025					FYE3/2026
   		FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q4 A	FY A	Q1
   														A	vs. Prev.Yr	%
   Current Assets	M	40,821	41,665	44,077	44,522	45,153	47,130	42,871	39,311	40,536	40,988	44,336	44,336	41,322	(3,014)	(6.8)
   Tangible Fixed Assets	M	9,914	9,920	11,341	13,111	12,911	12,452	13,434	13,416	13,527	13,739	13,285	13,285	13,256	(29)	(0.2)
   Intangible Fixed Assets	M	576	558	493	505	1,470	2,414	2,292	2,203	2,105	2,013	1,910	1,910	1,808	(101)	(5.3)
   Investments and Others	M	9,668	15,638	19,089	14,822	13,662	12,643	14,910	13,348	14,077	14,225	15,590	15,590	14,782	(808)	(5.2)
   Fixed Assets	M	20,159	26,117	30,923	28,439	28,044	27,510	30,638	28,968	29,710	29,979	30,786	30,786	29,847	(939)	(3.1)
   Total Assets	M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	68,280	70,246	70,967	75,123	75,123	71,169	(3,953)	(5.3)
   Current Liabilities	M	15,452	14,580	16,093	16,467	14,211	14,381	14,175	14,902	14,598	12,413	14,334	14,334	12,034	(2,300)	(16.0)
   Long-term Liabilities	M	4,438	6,709	7,500	5,190	4,418	4,063	1,231	1,116	1,023	978	874	874	789	(84)	(9.7)
   Total Liabilities	M	19,890	21,289	23,594	21,657	18,629	18,445	15,406	16,019	15,622	13,391	15,208	15,208	12,823	(2,385)	(15.7)
   Shareholder's Equity	M	41,088	46,496	51,618	51,267	54,362	56,265	57,516	51,495	53,792	56,428	58,675	58,675	57,289	(1,385)	(2.4)
   Accumulated other comprehensiv	M	(11)	(16)	(211)	37	205	(69)	585	764	831	1,147	1,239	1,239	1,056	(183)	(14.8)
   Share Warrant	M	13	13	ー	ー	ー	ー	ー	ー	ー	ー	ー	ー	ー	ー	ー
   Net Assets	M	41,090	46,493	51,406	51,304	54,567	56,195	58,102	52,260	54,624	57,576	59,914	59,914	58,346	(1,568)	(2.6)
   Total Liabilities and Net Assets	M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	68,280	70,246	70,967	75,123	75,123	71,169	(3,953)	(5.3)

   Cash and Deposits	M	6,732	8,018	9,555	13,708	16,058	18,357	12,669	7,010	8,047	7,890	11,014	11,014	7,467	(3,547)	(32.2)
   Accounts Receivables	M	12,331	12,178	13,762	13,145	12,437	13,223	13,283	14,248	13,875	14,229	13,830	13,830	14,170	＋340	＋2.5
   Inventory	M	13,579	17,071	18,187	15,987	14,850	13,142	15,154	16,151	16,841	17,034	17,961	17,961	18,188	＋227	＋1.3
   Accounts Payables	M	2,278	3,087	4,081	2,872	3,287	3,429	4,254	4,017	3,691	3,408	4,358	4,358	3,782	(576)	(13.2)
   Retained Earnings	M	25,091	30,499	35,912	35,352	38,890	42,741	47,291	46,478	48,573	51,208	53,455	53,455	52,035	(1,419)	(2.7)
   Interest-Bearing Debt	M	9,396	9,987	11,538	10,396	8,352	6,883	4,634	7,478	5,826	4,168	3,973	3,973	3,864	(108)	(2.7)
   Net Debt	M	2,663	1,968	1,983	(3,311)	(7,705)	(11,473)	(8,034)	468	(2,221)	(3,721)	(7,041)	(7,041)	(3,602)	＋3,438	(48.8)
   Invested Capital*1	M	50,484	56,484	63,156	61,663	62,714	63,148	62,151	58,974	59,619	60,597	62,648	62,648	61,154	(1,494)	(2.4)
   Working Capital*2	M	23,632	26,161	27,868	26,260	24,000	22,937	24,183	26,382	27,025	27,855	27,433	27,433	28,577	＋1,144	＋4.2

   *1 A sum of interest-bearing debt and shareholder's equity

   *2 Accounts receivables + Inventory - Accounts payables

3. Consolidated Cash Flows

   		FYE3/2018	FYE3/2019	FYE3/2020	FYE3/2021	FYE3/2022	FYE3/2023	FYE3/2024	FYE3/2025
   		FY A	FY A	FY A	FY A	FY A	FY A	FY A		FY A
   Operating Cash Flows	M	4,450	7,037	7,096	11,432	10,246	11,201	6,918		9,113
   Investing Cash Flows	M	(9,161)	(9,964)	(4,419)	(3,731)	(1,131)	(2,461)	(4,056)		(1,801)
   Financing Cash Flows	M	11,294	(1,783)	(1,136)	(3,720)	(6,804)	(6,476)	(8,553)		(9,040)
   Others	M	1	(3)	(4)	172	38	35	4		74
   Net change in cash and cash equiva	M	6,584	(4,713)	1,536	4,153	2,349	2,298	(5,688)		(1,654)
   Cash and cash equivalents at end of	M	12,732	8,018	9,555	13,708	16,058	18,357	12,669		11,014

4. Financial Indicators

   Amounts less than the indicated unit are rounded down.

   		FYE3/2018	FYE3/2019	FYE3/2020	FYE3/2021	FYE3/2022	FYE3/2023	FYE3/2024	FYE3/2025					FYE3/2026		FYE3/2026
   		FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q4 A	FY A	Q1 A		H1 E	H2 E	FY E
   No. of Issued Shares at YR-End (incl. treasury shares)	K	90,419	90,419	85,419	85,419	85,419	82,919	75,758	75,758	75,758	75,758	75,758	75,758	71,300		ー	ー	ー
   No. of Treasury Shares at YR-End*1	K	10,005	10,005	5,165	5,050	5,500	4,999	829	5,819	5,658	5,659	5,661	5,661	1,185		ー	ー	ー
   Ave No. of O/S Shares at YR-End (excl. treasury shares)*2	K	75,914	80,414	80,251	80,322	80,367	78,116	76,122	73,265	70,100	70,099	70,098	70,890	70,102		ー	ー	ー
   EPS*3		98.51	96.05	96.55	24.91	93.13	88.22	98.73	31.95	29.88	37.60	32.05	131.43	32.85		64.17 ーーーーーーーー	69.13 ーーーーーーーー	133.30
   BPS		510.81	578.01	640.54	638.36	682.79	721.20	775.43	747.23	779.24	821.35	854.74	854.74	832.15				928.71
   DPS		28.75	29.00	29.00	49.00	38.00	38.00	42.00	ー	ー	ー	ー	53.00	ー				54.00
   DOE %		7.3	5.3	4.8	7.7	5.8	5.4	5.6	ー	ー	ー	ー	6.5	ー				6.1
   Payout Ratio %		29.2	30.2	30.0	196.7	40.8	43.1	42.5	ー	ー	ー	ー	40.3	ー				40.5
   ROE %		24.2	17.6	15.8	3.9	14.1	12.4	13.2	ー	ー	ー	ー	15.8	ー				15.0
   ROA %		21.2	16.8	14.6	14.2	13.7	14.8	14.3	ー	ー	ー	ー	16.6	ー				16.8
   ROIC*4 %		14.7	13.7	12.1	11.5	11.1	11.9	12.1	ー	ー	ー	ー	13.7	ー				13.8
   Capital-to-Asset Ratio %		67.4	68.6	68.5	70.3	74.5	75.3	79.0	76.5	77.8	81.1	81.1	79.8	82.0				81.6
   Receivabes Turnover Period	Day	101	98	91	96	91	90	94	ー	ー	ー	ー	89	ー		ー	ー	86
   Inventory Turnover Period	Day	277	316	285	276	249	234	253	ー	ー	ー	ー	283	ー		ー	ー	280
   Payables Turnover Period	Day	48	55	58	56	50	56	69	ー	ー	ー	ー	70	ー		ー	ー	67
   Cash Conversion Cycle	Day	330	359	319	315	290	268	279	ー	ー	ー	ー	302	ー		ー	ー	300
   Number of Employees (Consolidated) Person		906	932	1,074	1,167	1,205	1,166	1,216	ー	ー	ー	ー	1,250	ー		ー	ー	ー

   *1 Company shares held by the BIP Trust for directors and Company shares held by the Trust for the Trust-type Employee Shareholding Incentive Plan (E-Ship) are included in treasury shares. (E-Ship terminated on July 29, 2021)

   *2 Values for each Q are for the accounting period

   *3 EPS after taking into account the stock split. A 1:2 stock split was carried out in Jan. 2018. In light of this, EPS for FY3/2018 is calculated assuming that the stock split took place at the beginning of the fiscal year

   *4 Denominator profit is operating profit after tax. After-tax operating profit = operating profit *(1 - effective tax rate (30.62%))

   *7 Cancellation of treasury shares: May 2019 5 million shares, July 2022 2.5 million shares, March 2024 7.16 million shares

5. Sales by Product

Amounts less than the indicated unit are rounded down.

FYE3/2018 FYE3/2019 FYE3/2020 FYE3/2021 FYE3/2022 FYE3/2023 FYE3/2024

FYE3/2025

FYE3/2026

FYE3/2026

Pacemaker*6 M

ICD*6 M

Others M

Cardiac Rhythm Management TTL M (CRM YoY) %

EP Catheter M

ABL Catheter M

Others M

EP/Ablation TTL M

(EP/ABL YoY) %

Artificial Heart Valve M

Vascular Graft M

Blood Purification*1 M

Others*3*5 M

Cardiovascular*４TTL M (CV YoY) %

Neurovascular*5 M

Neurovascular TTL M (NV YoY) %

Gastrointestinal M

Others*3 M

Gastrointestinal*2*3TTL M (GI YoY) %

Consolidated Net Sales M (Consolidated Net Sales YoY) %

*1 Included in "Others" since FYE3/2021

FY A

6,463

584

200

7,247

＋9.5

15,354

1,161

3,848

20,364

＋16.2

1,742

8,482

1,131

106

11,464

＋26.0

ーーー

28

3,193

3,221

＋15.7

42,298

＋13.8

FY A

5,169

496

196

5,862

(19.1)

17,028

1,369

4,662

23,060

＋13.2

1,448

9,133

1,070

77

11,730

＋2.3

ーーー

107

4,765

4,872

＋51.2

45,525

＋7.6

FY A

5,682

5,960

223

11,866

＋102.4

17,915

1,421

5,358

24,696

＋7.1

259

8,879

994

32

10,166

(13.3)

ーーー

132

4,900

5,032

＋3.3

51,761

＋13.7

FY A

5,996

7,001

250

13,248

＋11.7

17,314

1,047

5,501

23,863

(3.4)

ー 9,039

ー 929

9,969

(1.9)

ーーー

247

3,957

4,204

(16.5)

51,286

(0.9)

FY A

5,899

6,747

330

12,977

(2.0)

18,412

1,232

5,455

25,099

＋5.2

ー 9,368

ー 748

10,117

＋1.5

12

12

ー

453

2,808

3,261

(22.4)

51,469

＋0.4

FY A

4,979

7,049

374

12,403

(4.4)

19,654

1,011

5,626

26,292

＋4.8

ー 10,353

ー 423

10,776

＋6.5

230

230

＋1,753.6

654

1,394

2,048

(37.2)

51,750

＋0.5

FY A

5,241

7,857

402

13,501

＋8.9

21,211

840

2,197

24,249

(7.8)

ー 10,956

ー 449

11,406

＋5.9

912

912

＋296.7

925

388

1,314

(35.8)

51,384

(0.7)

Q1 A

1,381

1,978

109

3,469

＋0.7

5,971

204

925

7,101

＋13.2

ー 2,686

ー 97

2,784

＋2.5

347

347

＋157.5

273

33

307

(19.6)

14,010

＋8.2

Q2 A

1,098

2,035

121

3,256

＋1.0

5,711

187

1,122

7,021

＋19.6

ー 2,720

ー 151

2,871

＋11.5

452

452

＋107.0

324

48

373

＋29.9

13,974

＋14.8

Q3 A

1,114

2,171

107

3,393

(2.3)

5,766

153

1,310

7,229

＋20.3

ー 3,204

ー 135

3,339

＋8.8

491

491

＋82.5

350

20

371

＋6.4

14,825

＋12.6

Q4 A 911

2,111

125

3,148

(6.2)

5,093

102

1,296

6,492

＋6.5

ー 3,077

ー 132

3,210

＋5.5

550

550

＋90.1

396

0

397

＋34.1

13,799

＋5.5

FY A

4,506

8,296

464

13,267

(1.7)

22,543

647

4,654

27,845

＋14.8

ー 11,688

ー 517

12,206

＋7.0

1,842

1,842

＋101.9

1,345

103

1,448

＋10.2

56,610

＋10.2

Q1 A

1,049

2,136

199

3,386

(2.4)

5,653

87

1,535

7,276

＋2.5

ー 2,848

ー 161

3,010

＋8.1

562

562

＋61.9

352

28

380

＋23.9

14,616

＋4.3

YoY (332)

＋158

＋90 (83)

(317)

(116)

＋609

＋175

ー

＋161

ー

＋63

＋225

＋215

＋215

＋79 (5)

＋73

＋605

% (24.0)

＋8.0

＋82.1 (2.4)

(5.3)

(57.0)

＋65.9

＋2.5

ー

＋6.0

ー

＋65.3

＋8.1

＋61.9

＋61.9

＋29.0 (17.2)

＋23.9

＋4.3

H1 E

2,160

4,320

400

6,880

＋2.3

11,680

215

2,705

14,600

＋3.4

ー 5,590

ー 280

5,870

＋3.8

1,045

1,045

＋30.6

840

65

905

＋33.0

29,300

＋4.7

H2 E

1,980

3,890

480

6,350

(2.9)

11,730

195

2,620

14,545

＋6.0

ー 6,540

ー 240

6,780

＋3.5

1,215

1,215

＋16.6

1,055

55

1,110

＋44.4

30,000

＋4.8

FY E

4,140

8,210

880

13,230

(0.3)

23,410

410

5,325

29,145

＋4.7

ー 12,130

ー 520

12,650

＋3.6

2,260

2,260

＋22.7

1,895

120

2,015

＋39.1

59,300

＋4.8

YoY (366)

(86)

＋415 (37)

＋866 (237)

＋670

＋1,299

ー

＋441

ー

＋2

＋443

＋417

＋417

＋549

＋16

＋566

＋2,689

% (8.1)

(1.0)

＋89.6 (0.3)

＋3.8 (36.7)

＋14.4

＋4.7

ー

＋3.8

ー

＋0.5

＋3.6

＋22.7

＋22.7

＋40.9

＋15.7

＋39.1

＋4.8

*2 Renamed from "Transvascular Intervention" to "Gastrointestinal/PI" since FYE3/2023

*3 Renamed from "Gastrointestinal/PI" to "Gastrointestinal" since FYE3/2024 as PI businesses are downsized. Its subcategory "PI-related" is renamed to "Others". Sales of structural heart disease-related is moved to "Cardiovascular, Others" (Reclassifications)

*4 Renamed from "Cardiovascular Surgery" to "Cardiovascular" since FYE3/2024

*5 Sales of neurovascular-related is moved from "Cardiovascular, Others" to an new independent category of "Cardiovascular, Neurovascular" (Reclassifications)

*6 Sales of left ventricular pacing lead is moved from "ICD" to "Pacemaker" since FYE3/2024 (Reclassifications)

*7 Sales of neurovascular in the sub-groupe of CV is moved to a new independent main groupe (Reclassifications)

*8 Reclassifications regarding *3, *5, *6, and *7 are retroactively applied to FY2021 and onward.